Somatrem

What is Somatrem?

Somatrem is a synthetic form of human growth hormone (hGH), specifically a methionyl human growth hormone (met-hGH). It holds significant historical importance as the very first **recombinant human growth hormone** approved by the U.S. Food and Drug Administration (FDA) in 1985, marketed under the brand name **Protropin**. Developed using advanced recombinant DNA technology, Somatrem was designed to mimic the effects of naturally occurring human growth hormone, crucial for growth, metabolism, and body composition.

While groundbreaking, Somatrem structurally differs slightly from natural human growth hormone due to an extra methionine amino acid. This difference could, in some individuals, lead to antibody formation. This paved the way for the development of **somatropin**, which is structurally identical to endogenous hGH and largely replaced Somatrem in clinical practice due to its improved safety profile.

How Does it Work?

The mechanism of action of Somatrem closely mirrors that of natural human growth hormone. Upon administration, it binds to specific growth hormone receptors on target cells throughout the body. This binding initiates intracellular signaling pathways leading to various physiological effects. A primary action is the stimulation of the liver and other tissues to produce **insulin-like growth factor 1 (IGF-1)**. IGF-1 is a key mediator of growth hormone's actions, particularly in promoting linear bone growth in children and adolescents.

Beyond IGF-1 stimulation, Somatrem directly promotes protein synthesis, increasing lean body mass. It also influences carbohydrate and lipid metabolism, contributing to glucose homeostasis and fat breakdown. Essentially, Somatrem acts as an anabolic hormone, facilitating cell proliferation, tissue repair, and overall somatic growth, primarily in individuals with insufficient natural growth hormone production.

Medical Uses

Historically, the main medical use of Somatrem was the treatment of **growth hormone deficiency** (GHD) in children. Before recombinant growth hormones, hGH was obtained from cadaveric pituitary glands, carrying risks of transmitting infectious agents. Somatrem offered a safe and abundant supply, revolutionizing GHD treatment.

It was specifically indicated for children whose growth failure stemmed from inadequate endogenous growth hormone secretion. By supplementing the deficient hormone, it aimed to stimulate linear growth, helping children achieve a more normal adult height. However, its use was eventually phased out in favor of somatropin, which is structurally identical to natural human growth hormone and less likely to induce antibody formation. Today, somatropin is the standard treatment for GHD, making Somatrem largely a historical compound.

Dosage

The dosage of Somatrem, when in use, was highly individualized, determined by a healthcare professional based on the patient's condition, age, weight, and response. It was typically administered via subcutaneous injection, often daily or several times per week.

• Initial Dosing: Doses for children with growth hormone deficiency were calculated based on body weight or body surface area.
• Administration: Injections were given subcutaneously, usually in the thigh, arm, or abdomen, with site rotation to prevent local reactions.
• Monitoring: Patients required regular monitoring of growth parameters (height, weight), IGF-1 levels, and thyroid function. Dosage adjustments were made based on clinical response to optimize growth while minimizing side effects.

All growth hormone therapy requires strict medical supervision and should never be used without a prescription.

Side Effects

Like all medications, Somatrem could cause side effects. Common ones often included:

• Injection site reactions: Pain, redness, swelling, or bruising.
• Headache: Mild to moderate.
• Fluid retention: Mild edema.
• Musculoskeletal pain: Joint or muscle pain.

More serious, though less common, side effects included:

• Intracranial hypertension: Severe headache, nausea, vomiting, visual disturbances.
• Slipped capital femoral epiphysis: A hip joint condition in adolescents.
• Glucose intolerance: Potential for elevated blood glucose levels.
• Antibody formation: Could diminish effectiveness, a key reason for the shift to somatropin.
• Hypothyroidism: May be unmasked or worsened.

Patients were advised to report any unusual or persistent side effects to their healthcare provider.

Drug Interactions

Potential drug interactions were a crucial consideration for Somatrem therapy:

• Glucocorticoids: High doses can inhibit Somatrem's growth-promoting effects. Dosage adjustments or careful monitoring might be needed.
• Thyroid Hormones: Adequate thyroid levels are essential for full therapeutic effect. Thyroid function should be assessed and optimized.
• Insulin and Oral Hypoglycemic Agents: Growth hormone can affect carbohydrate metabolism. Diabetic patients might need adjustments to their medication due to potential blood glucose changes.
• Estrogens: High doses, especially oral, can decrease the serum IGF-1 response, potentially requiring higher Somatrem doses.

Patients should always inform their doctor about all medications and supplements.

FAQ

Is Somatrem still used today?

While historically important, Somatrem has been largely replaced by somatropin in clinical practice due to somatropin's identical structure to natural hGH and better safety profile. It is rarely prescribed today.

What is the difference between Somatrem and Somatropin?

Somatrem has an extra methionine amino acid compared to natural human growth hormone. Somatropin is identical in amino acid sequence to the human growth hormone produced by the pituitary gland.

How was Somatrem administered?

Somatrem was administered via subcutaneous injection, typically into the fatty tissue under the skin.

Who could use Somatrem?

Historically, Somatrem was prescribed primarily for children with confirmed **growth hormone deficiency** to promote linear growth.

Products containing Somatrem are available through trusted online pharmacies. You can browse Somatrem-based medications at ShipperVIP or Medicenter.

Summary

Somatrem marks a pivotal milestone as the first recombinant human growth hormone. Its introduction revolutionized the safe and effective treatment of **growth hormone deficiency** in children, replacing risky pituitary-derived hormones. Despite its extra methionine residue, which led to its eventual replacement by **somatropin**, Somatrem laid crucial groundwork for modern growth hormone therapies. Understanding its mechanism, historical uses, dosage, and side effects offers valuable insight into endocrinology's evolution. Though no longer widely used, its legacy significantly impacts current approaches to growth disorders.